cancer antigen 19–9 (ca 19–9  (Absolute Biotech Inc)

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: High-Sensitivity Detection of the Lung Cancer Biomarker CYFRA21-1 in Serum Samples Using a Carboxyl-MoS 2 Functional Film for SPR-Based Immunosensors

doi: 10.3389/fbioe.2020.00234

Figure Lengend Snippet: SPR sensorgram curves were analyzed for the CYFRA21-1 protein in spiked human serum samples using the carboxyl-MoS 2 -based chip. (A) Different serum concentrations were used to assess interference analysis during the test. (B) Comparisons of different serum ratios at SPR biosensing for interference analysis. (C) SPR curves for the quantitative detection of CYFRA21-1 protein using the S5 buffer spiked with different dilutions of CYFRA21-1 proteins. (D) The specificity of the biosensor tested the SPR responses to non-specific interfering biomarkers. The SPR responses to CA-199, hCG, PAPP-A, PAPP-A2, HSA, and CYFRA21-1 proteins mixed with S5 (6.25% serum) at a ratio of 1:1 in a total volume of 200 μL buffer were investigated.

Article Snippet: In the evaluated specificity test, we used different non-specific biomarkers at concentrations of 200 ng/mL each and a volume of 200 μL including cancer antigen 19-9 (CA-199, product number: MBS173342, MyBioSource Inc., United States), hCG (product number: 1297001, Sigma-Aldrich, United States), pregnancy-associated plasma protein A recombinant protein (PAPP-A, product number: MBS2011936, MyBioSource Inc., United States), pregnancy-associated plasma protein A2 recombinant protein (PAPP-A2, product number: MBS2011332, MyBioSource Inc., United States), and human serum albumin (HSA, ≥98%, product number: SRP618, Sigma-Aldrich, United States) proteins.

Techniques:

Journal: Cell

Article Title: FXR regulates intestinal cancer stem cell proliferation

doi: 10.1016/j.cell.2019.01.036

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Tumor markers, Carcinoembryonic Antigen (CEA) (Lifespan Biosciences Inc, cat #LS-F5042) and Cancer Antigen 19–9 (CA 19–9) (Lifespan Biosciences Inc, cat #LS- {"type":"entrez-nucleotide","attrs":{"text":"F24309","term_id":"4809935","term_text":"F24309"}} F24309 ) were used to distinguish between benign and malignant tumors.

Techniques: Generated, Recombinant, Acid Assay, Enzyme-linked Immunosorbent Assay, Cell Viability Assay, Viability Assay, Isolation, Flow Cytometry, Imaging, In Vivo, SYBR Green Assay, Western Blot, Sequencing, Software